DAWN - Company ID 0001845337
Day One Biopharmaceuticals, Inc. trades as DAWN and has a market capitalization of $2.22 B, making it the #2048 largest US-listed company by market value. In its fiscal 2025 annual report the company posted revenue of $158.18M, up 20.6% from the prior year and net income of -$107.32B. This page tracks Day One Biopharmaceuticals, Inc. through 493 SEC filings, with financial statements and metrics updated as new reports are filed.
Research snapshot
Updated
2026-06-25
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Next research step
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.
| Filing | Type | Filed |
|---|---|---|
| SCHEDULE 13G/A | - | 2026-05-15 |
| SCHEDULE 13G/A | - | 2026-05-14 |
| 15-12G | - | 2026-05-04 |
| SCHEDULE 13D/A | - | 2026-04-27 |
| Insider trade | 4 | 2026-04-27 |
| Insider trade | 4 | 2026-04-23 |
| Insider trade | 4 | 2026-04-23 |
| Insider trade | 4 | 2026-04-23 |
The largest companies sharing Day One Biopharmaceuticals, Inc.'s SEC industry classification (pharmaceutical preparations).
Day One Biopharmaceuticals, Inc. (DAWN) has a market capitalization of $2.22 B as of 2026-06-25, ranking #2048 among US-listed companies.
Day One Biopharmaceuticals, Inc. reported revenue of $158.18M for fiscal year 2025, an increase of 20.6% year over year.
In its latest fiscal year Day One Biopharmaceuticals, Inc. reported a net loss of $107.32B.